Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 11 , ISSUE 2 ( March-April, 2019 ) > List of Articles


Glanzmann's Thrombasthenia: A Review of Literature

Hansa Dhar, Asha Santosh

Keywords : Epistaxis, Glanzmann's thrombasthenia, Menorrhagia, Mucocutaneous bleeding, Platelet transfusion, rFν11a

Citation Information : Dhar H, Santosh A. Glanzmann's Thrombasthenia: A Review of Literature. J South Asian Feder Obs Gynae 2019; 11 (2):134-137.

DOI: 10.5005/jp-journals-10006-1665

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Introduction: Glanzmann's thrombasthenia is an inherited autosomal recessive bleeding disorder in which there is a deficiency of platelet glycoprotein GpIIb/IIIa. These receptors allow platelets to aggregate by sticking to each other, releasing granular contents to potentiate the process of clotting. Platelets are not able to clump together when stimulated, resulting in failure to form platelet aggregates. In such instances, bleeding time is prolonged and the clot retraction is defective, resulting in increased bleeding tendency. GT is diagnosed by tests that determine whether there is a deficiency of the α11bβ3 (GpIIb/IIIa) receptor. The diagnosis is confirmed mainly by flow cytometry and monoclonal antibodies. In the platelet function analyzer 100 (PFA-100), platelets fail to plug on the filter, as platelet aggregation response is defective. The condition may present in early childhood causing repeated nasal bleeds, or in adulthood as menorrhagia, antenatal, and postpartum hemorrhage. Patients may require many leukocyte-depleted blood products during bleeding episodes. Objectives: Objectives of this review article is to understand the implications of Glanzmann's thrombasthenia, its pathogenesis, diagnostic modalities and treatment options as it is a rare platelet disorder. Surgeons have to be on the alert if the case is a Glanzmann's thrombasthenia, as uncontrolled hemorrhage not responding to usual treatment can have fatal consequences. Materials and methods: An extensive search and review of current literature was undertaken via PubMed and EMBASE to know the historical background with its latest management options available. Results and evidence: Studies have suggested that GT is a hereditary disorder occurring predominantly in consanguineous populations with female preponderance. Remarks and conclusions: As consanguinity is very high in this part of the world awareness among clinicians of this medical disorder is necessary to avoid unanticipated hemorrhage and its untoward complications.

  1. Glanzmann E. Hereditare Hamorrhgische thrombasthenie. Ein Beitrag Zur Pathologie der Blutplattchen. J Kinderkranken 1918;88:113.
  2. Braunsteiner H, Pakeschf F. Thrombocytoasthenia and thrombocytopathia. Old names and new diseases. Blood 1956;11:965–976.
  3. Caen JP, Castaldi PA, et al. Glanzmann's thrombasthenia. I. Congenital bleeding disorders with long bleeding time and normal platelet count. Am J Med 1966;44:4–10. DOI: 10.1016/0002-9343(66)90003-9.
  4. George JN, Caen JP, et al. Glanzmann's thrombasthenia: The spectrum of clinical disease. Blood 1990;75:1383–1395.
  5. Nair S, Ghosh K, et al. Glanzmann's Thrombasthenia: Updated. Platelets 2002;13:387–393. DOI: 10.1080/0953710021000024394.
  6. Kannan M, Saxena R. Glanzmann's thrombasthenia: An overwiew. Clin Appl Thromb Hemost 2009;15:152–165. DOI: 10.1177/1076029608326165.
  7. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006;1:10. DOI: 10.1186/1750-1172-1-10.
  8. Saxena R, Kannan M. Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost 2008;16.
  9. Ghoshal K, Bhattacharyya M. Overview of Platelet Physiology: Its Hemostatic and Nonhemostatic Role in Disease Pathogenesis. The Scientific World Journal 2014;7(81):857–873. DOI: 10.1155/2014/781857.
  10. Nurden AT, Fiore M, et al. Glanzmann thrombasthenia: a review of IT GA2B & ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011;118(23):5996–6005. DOI: 10.1182/blood-2011-07-365635.
  11. Siddiq S, Clark A, et al. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011;17(5):e858–e869. DOI: 10.1111/j.1365-2516.2011.02516.x.
  12. Ambreen M, Yasmeen S, et al. Glanzmann's Thrombasthenia. Ann Pak Inst Med Sci 2010;7(1):47–49.
  13. Di Minno G, Coppola A, et al. Glanzmann's thrombasthenia (defective platelet integrin alpha 11b-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009;102(6):1157–1164. DOI: 10.1160/TH09-04-0225.
  14. Van de Vijver E, De Cuyper IM, et al. Defects in Glanzmann thrombasthenia and LAD -111(LAD-1/V) syndrome: the role of integrin β1 and β3 in platelet adhesion to collagen. Blood 2011;119:583–586. DOI: 10.1182/blood-2011-02-337188.
  15. Fiore M, Nurden AT, et al. Clinical utility gene card for: Glanzmann thrombasthenia. Eur J Hum Genet 2012;20. DOI: 10.1038/ejhg. 2012.151.
  16. Tokgoz H, Ozkan DT, et al. Novel mutations of the integrin α11b and β3 genes in Turkish children with Glanzmann's thrombasthenia. Platelets 2015;26(8):779–782. DOI: 10.3109/09537104.2014.998994.
  17. Recht M, Chitlur M, et al. Epistaxis as a common Presenting symptom of Glanzmann's Thrombasthenia, A Rare Qualitative Platelet Disorder: Illustrative case examples. Case Rep Emerg Med 2017;8796:425–430. DOI: 10.1155/2017/8796425.
  18. Trasi SA, Pathare AV, et al. The spectrum of bleeding disorders in women with menorrhagia: a report from western India. Ann Hematol 2005;84:339–342. DOI: 10.1007/s00277-004-0905-4.
  19. Awidi AS. Delivery of infants with Glanzmann's Thrombasthenia and subsequent blood transfusion requirements: a follow up of 39 patients. Am J Hematol 1992;40:1–4. DOI: 10.1002/ajh.2830400102.
  20. Ali N, Moiz B, et al. Diagnostic tool for Glanzmann's thrombasthenia clinicopathologic Spectrum. J Coll Physicians Surg Pak 2008;18(2): 91–94.
  21. Nurden AT, Ruan J, et al. A novel 196 Leu to Pro substitution in the beta 3 subunit of the alpha 11 beta integrim in a patient with a variant form of Glanzmann thrombasthenia. Platelets 2002;13:101–111. DOI: 10.1080/09537100220122466.
  22. Kashiwagi H, Kunishima S, et al. Demonstration of novel gain-of– function mutation of α11bβ3: association with macrothrombocytopenia and Glanzmann thrombasthenia – like phenotype. Mol Genet Genomic Med 2013;1:77–86. DOI: 10.1002/mgg3.9.
  23. Magudapathi C, Kannan S. Glanzmann's Thrombasthenia Complicating Pregnancy. J Obstet Gynaecol India 2014;64(1):3–5. DOI: 10.1007/s13224-012-0319-5.
  24. Di Michele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990;33:39–45.
  25. Majed KS, Al Nounou R. Glanzmann's Thrombasthenia, Correlation by Flow, Platelet Aggregometry and Platelet Function Assay (PFA). Bahrain Med Bull 2015;37(1):20–22. DOI: 10.12816/0014395.
  26. Kazemzadeh S, Mohammadi R, et al. Methylene tetrahydrofolate Reductase Polymorphisms in Iranian Patients with Glanzmann's Thrombasthenia. Ira J Ped Hematol Oncol 2016;7(1):48–56.
  27. Saboor M, Moinuddin M, et al. New Horizons in Platelets Flow Cytometry. Malays J Med Sci 2013;20(2):62–66.
  28. Diz-Kucukkaya R. Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome. Hematology Am Soc Hematol Edu Program 2013;2013:268–275. DOI: 10.1182/asheducation-2013.1.268.
  29. Linder MD, Frelinger AL 3rd, et al. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004;30:501–511. DOI: 10.1055/s-2004-835671.
  30. Peerschke EI. The laboratory evaluation of platelet dysfunction. Clin Lab Med 2002;22:405–420. DOI: 10.1016/S0272-2712(01) 00008-7.
  31. Robinson L, Gorton H. Thromboelastography: validation of the Thromboelastograph: 3000 and Thromboelastograph 5000. Br J Anaesth 2001;86:309–312.
  32. Narani KK. Thrombelastography in the preoperative period. Indian J Anaesth 2005;49(2):89–95.
  33. Chitlur M, Rivard GE, et al. Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12:103–106. DOI: 10.1111/jth.12458.
  34. Loroch S, Trabold K, et al. Alterations of the platelet ptoteome in type 1 Glanzmann thrombasthenia caused by different homozygous de IG frame shift mutations in ITGA2B. Thromb Haemost 2017;117(3): 556–569. DOI: 10.1160/TH16-07-0515.
  35. Kumar N, Khan AA, et al. Glanzmann thrombasthenia and its perioperative management in head trauma: a rare and challenging situation. J Neuroanaesthesiol Crit Care 2016;3:52–55. DOI: 10.4103/2348-0548.173235.
  36. Fernandes Gomes M, de Melo RM, et al. Surgical and clinical management of a patient with Glanzmann thrombasthenia: a case report. Quintessence Int 2004;35(8):617–620.
  37. Brown SR. Antifibrinolytic Drugs (Aminocaproic acid and Tranexamic Acid): Treatment perspectives for Dental Surgery. Curr Oral Health Rep 2015;2:143–147. DOI: 10.1007/s40496-015-0051-1.
  38. Yepes JF, Sullivan JA, et al. Hypercoagulability syndrome: What the dentist needs to know. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104(1):3–11. DOI: 10.1016/j.tripleo.2006.11.023.
  39. Wardrop D, Estcourt LJ, et al. Antifibrinolytics (Lysine analogues) for the prevention of bleeding in patients with haematological disorders (review). Cochrane Database Syst Rev 2013;7:CD009733.
  40. Bloor AJ, Smith GA, et al. Acquired thrombasthenia due to GP11b111a platelet antibodies in a 4-year old child. Eur J Haematol 2006;76: 89–90. DOI: 10.1111/j.1600-0609.2005.00574.x.
  41. Poon MC. Clinical use of recombinant human V11 (rFV11a) in the prevention and treatment of bleeding episodesin patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag 2007;3(5): 655–664.
  42. Rajpurkar M, Chitlur C, et al. Use of recombinant activated Factor ν11 in patients with Glanzmann's Thrombasthenia: a review of the literature. Haemophilia 2014;20(4):464–471. DOI: 10.1111/hae. 12473.
  43. Ayub M, Islam A. Glanzmann's Thrombasthenia; A Review study. PRJNHS 2016;2(1):46–52.
  44. Marlu R, Barthelon J, et al. Long-term Therapy with Bevacizumab in a patient with Glanzmann's Thrombasthenia and Recurrent Digestive Bleeding due to Gastrointestinal Angiodysplastic Lesions. Am J Gastroenterl 2015;110(2):352–353. DOI: 10.1038/ajg. 2014.391.
  45. Barre A, Dreanic J, et al. Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia? Haemophilia 2016;22(4):347–348. DOI: 10.1111/hae.12977.
  46. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004;103:390–398. DOI: 10.1182/blood-2003-05-1742.
  47. Duarte BKL, de Souza SM, et al. Thalidomide for the treatment of gastrointestinal bleeding due to angiodysplasia in a patient with Glanzmann's thrombasthenia. Hematology Reports 2017;9:53–56. DOI: 10.4081/hr.2017.6961.
  48. Wilcox DA, White GC. Gene therapy for Platelet disorders: Studies with Glanzmann's Thrombasthenia. J Thromb Haemost 2003;1(11): 2300–2311. DOI: 10.1046/j.1538-7836.2003.00476.x.
  49. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004;104:1606–1615. DOI: 10.1182/blood-2004-04-1257.
  50. Kunicki TJ, Federici AB, et al. An association of candidate gene haplotype and bleeding severity in Von Willebrand disease (VWD) type 1 pedigrees. Blood 2004;104:2359–2367. DOI: 10.1182/blood-2004-01-0349.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.